We are live on ! Find out more
ABUS icon

Arbutus Biopharma
ABUS

55 hedge funds and large institutions have $88.8M invested in Arbutus Biopharma in 2016 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 23 increasing their positions, 12 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 7

92% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 12

65.99% more ownership

Funds ownership: 0% → 65.99% (+66%)

15% more funds holding

Funds holding: 48 → 55 (+7)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

23% less capital invested

Capital invested by funds: $115M → $88.8M (-$26.2M)

48% less call options, than puts

Call options by funds: $620K | Put options by funds: $1.19M

Holders
55
Holders Change
+7
Holders Change %
+14.58%
% of All Funds
1.38%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
14
Increased
23
Reduced
12
Closed
7
Calls
$620K
Puts
$1.19M
Net Calls
-$567K
Net Calls Change
-$628K

Top Buyers

Rank Fund Capital Flow
1
LTFS
Ladenburg Thalmann Financial Services
Florida
+$15.4M
2
AC
Armistice Capital
New York
+$1.57M
3
KPF
K2 Principal Fund
Ontario, Canada
+$978K
4
DCM
DAFNA Capital Management
California
+$681K
5
OAM
Oxford Asset Management
United Kingdom
+$466K

Top Sellers

Rank Fund Capital Flow
1
HM
HealthCor Management
New York
-$6.88M
2
AWG
Alpha Wave Global
New York
-$2.8M
3
Millennium Management
Millennium Management
New York
-$1.33M
4
SCM
Suffolk Capital Management
New York
-$1.08M
5
SFM
Sphera Funds Management
Israel
-$809K
Name Holding Trade Value Shares
Change 		Change in
Stake
Group One Trading
26
Group One Trading
Illinois
$110K +$62.3K +21,398 +91%
Mackenzie Financial
27
Mackenzie Financial
Ontario, Canada
$98K – – –
DTL
28
Dynamic Technology Lab
Singapore
$98K +$116K +40,017 New
Citadel Advisors
29
Citadel Advisors
Florida
$93K +$111K +38,148 New
SC
30
Scotia Capital
Ontario, Canada
$87K +$103K +35,500 New
Geode Capital Management
31
Geode Capital Management
Massachusetts
$65K +$1.66K +572 +2%
WS
32
Wedbush Securities
California
$62K +$24.7K +8,500 +50%
DCM
33
Dialectic Capital Management
Connecticut
$61K +$72.7K +25,000 New
VKH
34
Virtu KCG Holdings
New York
$58K -$17K -5,857 -20%
SFM
35
Sphera Funds Management
Israel
$54K -$809K -278,000 -93%
Royal Bank of Canada
36
Royal Bank of Canada
Ontario, Canada
$52K +$24.1K +8,280 +64%
Millennium Management
37
Millennium Management
New York
$47K -$1.33M -456,918 -96%
Fidelity Investments
38
Fidelity Investments
Massachusetts
$47K – – –
TC
39
TFS Capital
Pennsylvania
$35K +$41.3K +14,195 New
Renaissance Technologies
40
Renaissance Technologies
New York
$34K -$297K -102,026 -88%
Squarepoint
41
Squarepoint
New York
$33K +$39K +13,400 New
State Street
42
State Street
Massachusetts
$30K +$1.48K +510 +4%
CG
43
Cutler Group
California
$28K +$5.19K +1,784 +18%
JG
44
Jefferies Group
New York
$25K -$2.62K -900 -8%
JP Morgan Chase
45
JP Morgan Chase
New York
$24K +$28.2K +9,700 New
TRCT
46
Tower Research Capital (TRC)
New York
$21K +$20.9K +7,180 +488%
Walleye Trading
47
Walleye Trading
New York
$17K +$20.4K +7,000 New
Wells Fargo
48
Wells Fargo
California
$8K +$582 +200 +7%
Bank of America
49
Bank of America
North Carolina
$6K +$1.46K +500 +26%
Creative Planning
50
Creative Planning
Kansas
$4K +$1.46K +500 +50%
1
2
3

ABUS Hedge Fund Activity: Q4 2016 in Review

55 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q4 2016, worth a combined $88.8M — down 23% from $115M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new ABUS positions and 7 closed out — a net gain of 7 holders — while 23 added to existing stakes and 12 trimmed.

The largest buyer was Ladenburg Thalmann Financial Services, adding an estimated $15.4M. The largest seller was HealthCor Management, exiting entirely with an estimated $6.88M sold.

  • 55 institutional investors held Arbutus Biopharma (ABUS) as of Q4 2016, up from 48 in Q3 2016.
  • Funds reported $88.8M of Arbutus Biopharma stock for Q4 2016, down 23% quarter-over-quarter.
  • 14 funds opened new Arbutus Biopharma positions in Q4 2016 and 7 closed out, a net change of +7 holders.
  • The largest Arbutus Biopharma buyer in Q4 2016 was Ladenburg Thalmann Financial Services, an estimated $15.4M added.
  • The largest Arbutus Biopharma seller in Q4 2016 was HealthCor Management, an estimated $6.88M sold.

Based on aggregated 13F filings for Q4 2016.